This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schweizer, A. Articles by Brunel, P. Search for Related Content Social Bookmarking                         What's this?

Comparison of the postprandial glucose and insulin profiles with nateglinide and gliclazide in type 2 diabetic patients

Novartis Pharma AG, Basel, Switzerland, anja.schweizer{at}pharma.novartis.com

Michele Ball

Novartis Pharmaceuticals Corp, East Hanover, NJ, USA

David R Owens

Diabetes Research Unit, Landough Hospital, Penarth, Wales

Floriane Cressier

Novartis Pharma AG, Basel, Switzerland

David O Holmes

Novartis Pharma AG, Basel, Switzerland

Patrick Brunel

Novartis Pharma AG, Basel, Switzerland

Aim

The aim of this study was to compare glucose, insulin and proinsulin profiles during nateglinide and gliclazide treatment over an extended postprandial period.

Materials and methods

This double-blind crossover trial was conducted in 23 type 2 diabetic patients (mean HbA1C 6.6%; range 6.0—7.4%) who received, for one week each, nateglinide 120 mg t.i.d., gliclazide 80 mg b.i.d. and placebo, with a one week wash out period between treatments.

Results

The 2-hour postprandial glucose concentration was markedly lower with nateglinide than with gliclazide (5.83 vs. 7.21 mmol/L; p<0.05), as was the post-meal peak glucose elevation (8.63 vs. 9.72 mmol/L; p=0.085), which was associated with earlier, higher and shorter-lived insulin and proinsulin secretory responses. However, 0—7-hour AUCs during standardised meal test for glucose and insulin between the two drugs did not statistically differ. No symptomatic hypoglycaemic events occurred during the 7-hour test period.

Conclusion

Nateglinide was more effective than gliclazide in controlling postprandial hyperglycaemia and showed a faster effect on insulin and proinsulin secretion.

Key Words: postprandial • glucose • hypoglycaemia • insulin • proinsulin • nateglinide • gliclazide.

References

• Harrower AD Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf 2000;22:313-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Van Staa T., Abenhaim L., Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Damsbo P., Clauson P., Marbury TC, Windfeld K. A double-blind randomized comparison of meal-regulated glycaemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999; 22:789-94.[Abstract/Free Full Text]
• Marbury T., Huang WC, Strange P., Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43:155-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Landgraf R., Bilo HJ, Muller PG A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999;55:165-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stahl M., Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999;16:586-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Palmer KJ, Brogden RN Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993;46:92-125.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• O'Brien RC, Luo M., Balazs N., Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complicat 2000;14:201-06.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Jennings PE Vascular benefits of gliclazide beyond glycaemic control. Metabolism 2000;49(suppl 2):17-20.[Web of Science][Medline] [Order article via Infotrieve]
• Halas CJ Nateglinide. Am J Health Syst Pharm 2001;58:1200-05.[Abstract/Free Full Text]
• Dunn CJ, Faulds D. Nateglinide. Drugs 2000;60:607-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sato Y., Nishikawa M., Shinkai H., Sukegawa E. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 1991;12:53-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes mellitus. Diabet Med 2000;17:225-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ikenoue T., Akiyoshi M., Fujitani S., Okazaki K., Kondo N., Maki T. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Br J Pharmacol 1997;120:137-45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hanefeld M., Bouter KP, Dickinson S Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycaemia. Diabetes Care 2000;23:202-07.[Abstract]
• Hollander PA, Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983-8.[Abstract/Free Full Text]
• Keilson L., Mather S., Walter YH, Subramanian S., McLeod JF Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85: 1081-6.[Abstract/Free Full Text]
• Walter YH, Spratt DI, Garreffa S., McLeod JF Mealtime glucose regulation by nateglinide in type 2 diabetes mellitus. Eur J Clin Pharmacol 2000;56: 129-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Levien TL, Baker DE, Campbell RK, White JR Nateglinide therapy for type 2 diabetes mellitus. Ann Pharmacother 2001;35:1426-34.[Abstract/Free Full Text]
• Kikuchi M. Modulation of insulin secretion in non-insulin dependent diabetes mellitus by two novel oral hypoglycemic agents, NN623 and A4166. Diabet Med 1996;13(suppl 6):S151-5.[Web of Science][Medline] [Order article via Infotrieve]
• Ikenoue T., Okazaki K., Fujitani S. et al. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull 1997;20:354-9.[Web of Science][Medline] [Order article via Infotrieve]
• de Souza CJ, Russo P., Lozito R., Dunning BE Differential effects and long duration insulinotropic agents on meal-related glucose excursions. Diabetes Obes Metab 2001;3:73-83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kjems LL, Roder ME, Dinesen B., Hartling SJ, Jorgensen PN, Binder C. Highly sensitive enzyme immunoassay of proinsulin inmmunoreactivity with use of two monoclonal antibodies. Clin Chem 1993;39:2146-50.[Abstract]
• Prescott RJ The comparison of success rates in crossover trials in the presence of an order effect. Applied Statistics 1981;30:9-15.[CrossRef]
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996;28:426-9.[Web of Science][Medline] [Order article via Infotrieve]
• Jennings AM, Wilson RM, Ward RJ Symptomatic hyperglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989;12: 203-08.[Abstract]
• Guay DR Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy 1998;18:1195-204.[Web of Science][Medline] [Order article via Infotrieve]
• Fujitani S., Okazaki K., Yada T. The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition. Br J Pharmacol 1997;120: 1191-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• de Souza CJ, Gagen K., Chen W., Dragonas N. Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus. Diabetes Obes Metab 2001;3:85-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Akanuma Y., Kosaka K., Kanazawa Y., Kasuga M., Fukuda M., Aoki S. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. Diabetes Res Clin Pract 1988;13:81-90.
• Ligtenberg JM, Reitsma WD, van Haeften TW Gliclazide mainly affects insulin secretion in the second phase of type 2 diabetes mellitus. Horm Metab Res 2001;33:361-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Avignon A., Radauceanu A., Mounier L. Nonfasting plasma glucose is a better marker of diabetic control then fasting plasma glucose in type 2 diabetes. Diabetes Care 1997;20:1822-6.[Abstract]
• Bonora E., Calcaterra F., Lombardi S. et al. Plasma glucose levels throughout the day and HbA1C interrelationships in type 2 diabetes. Implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24: 2023-9.[Abstract/Free Full Text]
• The DECODE Study Group. European Diabetes Epidemiology Study Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999:354:617-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000;16:125-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 3, 228-232 (2002)
DOI: 10.1177/14746514020020031601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schweizer, A. Articles by Brunel, P. Search for Related Content Social Bookmarking                         What's this?